Vertex Pharmaceuticals’ cell therapy zimislecel showed promising Phase 1/2 results in type 1 diabetes, with most patients achieving insulin independence and controlled blood glucose one year post-treatment, supporting ongoing pivotal trial enrollment. Concurrently, a novel oral molecule acting as a GRK-biased β2 adrenergic receptor partial agonist offers a potential alternative to injectable GLP-1 treatments for type 2 diabetes and obesity, demonstrating metabolic benefits in early trials without typical side effects like muscle loss. These developments reflect a growing therapeutic pipeline tackling diabetes across patient populations.